OrthoBio Market: SmartTRAK Predicts strong Growth Ahead

Robust growth is predicted for the US OrthoBio market, driving revenues to over $4B by 2021E according to SmartTRAK projections.

• Bone Replacement remains the largest segment of the US
• Bone Replacement remains the largest segment of the US OrthoBio market, accounting for over 50% of total 2016 revenues, followed by Joint Fluid at nearly 30% based on 2016 SmartTRAK Financial Dashboard results.  Next in line are Knee Ligament Grafts, Cartilage, Soft Tissue and Meniscus replacement which account for the remainder...

• Going forward, technologies for Cartilage and Meniscal Replacement will experience the greatest growth over the forecast period as new technologies make their way through the FDA process.
• Mature segments such as Bone Replacement and Knee Ligament Grafts will see CAGRs in the ~3.0%+ range while Soft Tissue Augmentation and Joint Fluid will be in the neighborhood of ~5.0%, based on SmartTRAK projections.
• New premium priced products (Stem cells, Cellular based, Growth factors) will fuel expansion of the US Bone Replacement Market, to over $2B by 2021E.
• With several new technologies in FDA trials, the US Cartilage Replacement Market (for knee and ankle indications) is projected at to reach over $200MM by 2021E
• Recently launched synthetic technologies for partial meniscal replacement, along with introduction of prosthetic implants for total replacement in the 2018-2019 timeframe, will reinvigorate the US Meniscus Replacement Market, comprised today solely of allograft transplants.
• Composed of products used for reinforcing or augmenting orthopedic tissues, the US Soft Tissue Augmentation Market will reach over $100MM in 2021E.
• The US market for Knee Ligament Replacement, consisting of Tendon Allografts, is projected to exceed $220.5MM in 2021E.
• The US Joint Fluid Replacement Market will be driven by continued adoption of higher-priced single injection products, expanding indications and the launch of new, novel products that provide longer-lasting pain relief.
• On the competitive front, the top five contenders in the 2016 US OrthoBio Market include: Medtronic, leading player; followed by Depuy Synthes; joint fluid supplier Sanofi; Zimmer Biomet and Ferring, according to SmartTRAK Financial Dashboard results. With over 250 companies participating in this field, it is not surprising that the “Other” category accounts for more than 40% of total OrthoBio revenues in 2016.